Clinical Pharmacokinetics of Lornoxicam

@article{Skjodt1998ClinicalPO,
  title={Clinical Pharmacokinetics of Lornoxicam},
  author={N. Skjodt and N. M. Davies},
  journal={Clinical Pharmacokinetics},
  year={1998},
  volume={34},
  pages={421-428}
}
  • N. Skjodt, N. M. Davies
  • Published 1998
  • Chemistry, Medicine
  • Clinical Pharmacokinetics
  • SummaryLornoxicam (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5′-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation. Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.Lornoxicam and its metabolites bind extensively to plasma albumin… CONTINUE READING
    IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?
    • 99
    • Open Access
    Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex
    • 18
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 22 REFERENCES